King Pharmaceuticals Income Statement
View: Annual | Quarterly
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 1,565.1 | 2,136.9 | 1,988.5 |
| Cost of Goods Sold | 394.8 | 789.6 | 567.4 |
| Gross Profit | 1,170.2 | 1,347.3 | 1,421.1 |
| Gross Profit Margin | 74.8% | 63.1% | 71.5% |
| SG&A Expense | 446.0 | 691.0 | 714.0 |
| Depreciation & Amortization | 150.7 | 173.9 | 147.5 |
| Operating Income | (193.8) | 258.6 | 434.2 |
| Operating Margin | -- | 12.1% | 21.8% |
| Nonoperating Income | (11.1) | (11.4) | (0.5) |
| Nonoperating Expenses | 29.0 | -- | -- |
| Income Before Taxes | (201.7) | 250.8 | 424.3 |
| Income Taxes | 131.4 | 67.6 | 135.7 |
| Net Income After Taxes | (333.1) | 183.2 | 288.6 |
| Continuing Operations | (333.1) | 183.2 | 288.6 |
| Discontinued Operations | 0.0 | (0.2) | 0.4 |
| Total Operations | (333.1) | 183.0 | 288.9 |
| Total Net Income | (333.1) | 183.0 | 288.9 |
| Net Profit Margin | -- | 8.6% | 14.5% |
| Diluted EPS from Total Net Income ($) | (1.37) | 0.75 | 1.19 |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
